• #LGM Pharma is a Metoprolol CAS# 51384-51-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 51384-51-1
  • AHFC code:
  • Synonyms: (RS)-Metoprolol, Beatrolol, Betaloc, CCRIS 4198, CGP 2175, Corvitol, dl-Metoprolol, EINECS 257-166-4, HSDB 6531, Loresor, Meijoprolol, Metohexal, Metoprolol, Metoprololum, Metoprololum [INN-Latin], Metrol, Minax, Neobloc, Preblok, Presolol, Selokeen, Seroken, Spesicor, Toprol, UNII-GEB06NHM23
  • ATC Code:
  • Chemical Formula: C15-H25-N-O3
  • Molecular Weight: 267.3665
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00264
  • SMILES: N(CC(COc1ccc(cc1)CCOC)O)C(C)C
  • InChl: 1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
  • PubChem:
  • IUPAC: 1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol

Additional Details

For the management of acute myocardial infarction, angina pectoris, heart failure and mild to moderate hypertension. May be used to treat supraventricular and tachyarrhythmias and as prophylaxis for migraine headaches.
Metoprolol, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).
Mode of Action:
Metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure.
Primarily hepatic
LD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice)
General Reference:
: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999 Jun 12;353(9169):2001-7. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials


Related YouTube Videos